ArticleFrontiers in oncology2024

FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study.

Wenwei Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.